Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
41.58 EUR | +1.77% | -2.47% | -9.00% |
Apr. 29 | STRATEC BIOMEDICAL SYSTEMS AG : Deutsche Bank reiterates its Neutral rating | ZD |
Apr. 26 | STRATEC BIOMEDICAL SYSTEMS AG : Berenberg reiterates its Neutral rating | ZD |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- With a 2024 P/E ratio at 30.42 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-9.00% | 535M | B+ | ||
+8.88% | 221B | B | ||
+8.68% | 186B | B- | ||
+14.25% | 137B | B- | ||
+28.18% | 109B | A- | ||
+14.65% | 52.68B | B+ | ||
+4.48% | 50.86B | B+ | ||
+4.39% | 42.53B | A | ||
+7.00% | 37.76B | - | ||
+26.06% | 31.86B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SBS Stock
- Ratings Stratec SE